{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-002096","form_type":"8-K","ticker":"AGPU","cik":"0001446159","company_name":"Axe Compute Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.102652+00:00","generated_at":"2026-05-15T08:08:31.999502+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Axe Compute reports FY2025 net loss of $232.9M; no compute revenue; holds $40M in ATH tokens","bullets":["Total revenue $125,284, entirely from legacy Drug Discovery; no compute revenue in 2025.","Net loss from continuing ops $232.9M, including $152.5M unrealized loss on digital assets (ATH) and $52.7M derivative loss.","Cash and equivalents $10.8M vs $0.6M; stockholders' equity improved to $47.7M from deficit of $0.2M.","Held 6.348B ATH tokens aggregate ($40M FMV after discount); $343.5M raised via PIPE in Oct 2025.","CEO Christopher Miglino appointed Feb 2026; board reconstituted; GPU network access over 435,000 GPUs established."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-002096","json":"https://secwatch.observer/filing/0001171843-26-002096.json","markdown":"https://secwatch.observer/filing/0001171843-26-002096.md","text":"https://secwatch.observer/filing/0001171843-26-002096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446159/000117184326002096/0001171843-26-002096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446159/000117184326002096/f8k_033126.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:08:31.999502+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c82b4fd71595ca6b37acb86664f7f63a9a7e59fe","claim":"Axe Compute Inc. reported the fiscal year ended December 31, 2025 results: revenue $125,284, net income $232.9 million.","evidence_excerpt":"center facilities or GPU hardware; the Company’s platform provides marketplace access to this network on an asset-light model. FULL YEAR 2025 FINANCIAL HIGHLIGHTS Total Revenue: $125,284, derived entirely from the Company’s Drug Discovery Services legacy segment. No compute revenue was recognized in fiscal 2025, as the Axe Compute segment launched in September 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446159/000117184326002096/0001171843-26-002096-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2025"},{"label":"Revenue","value":"$125,284"},{"label":"Net income","value":"$232.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}